NYSE • Healthcare • Drug Manufacturers - Specialty & Generic • JP • USD
Takeda Pharmaceutical Company Limited (TAK) has a consensus analyst rating of Buy, based on 6 analysts covering the stock. Of those, 5 recommend buying, 1 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
